Literature DB >> 30524602

Recurrent intra-cardiac thrombosis-A unique presentation of prothrombin G20210 mutation.

Kartika Shetty1, Nirmal Sunkara1, Chowdhury Ahsan1.   

Abstract

We report a 49-year-old female patient with recurrent large left ventricular thrombus on echocardiogram in an apparently normal heart and insignificant cardiac past medical history. She underwent an excision of the left ventricular mass, final biopsy on which proved it to be a thrombus. Postoperative anti-coagulation was initiated with enoxaparin and warfarin and the patient was followed up at a cardiology clinic 6 weeks later. A repeat trans-thoracic echocardiogram revealed a new mass arising from the left atrium. Considering the increased risk of repeat ventriculostomy, she was treated conservatively with her current management. During this time the patient's pro-thrombotic work-up revealed positive prothrombin G20210 mutation. A follow up trans-thoracic echocardiogram done 2 months later surprisingly revealed complete resolution of the intracardiac mass. Our patient had prothrombin G20210 mutation, an entity primarily known for deep venous thrombosis, which rarely causes intra-arterial thrombus, intra-cardiac being unreported. There are no established protocols for management of these cases. The rate of embolic episodes in mobile pedunculated thrombi is reported as high as 60%. Patients with prior embolism must be offered immediate surgery, especially if the thrombus is large with an irregular surface, pedunculated, and multiple in number. Aggressive anti-coagulation with close monitoring is essential.

Entities:  

Keywords:  Genetics; Pathogenesis; Prothrombin G20210 mutation; Recurrent intra-cardiac thrombus; Thrombosis

Year:  2011        PMID: 30524602      PMCID: PMC6265019          DOI: 10.1016/j.jccase.2011.02.002

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  20 in total

1.  No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study.

Authors:  Adam M Smiles; Nancy S Jenny; Zhonghua Tang; Alice Arnold; Mary Cushman; Russell P Tracy
Journal:  Thromb Haemost       Date:  2002-04       Impact factor: 5.249

2.  G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men.

Authors:  P M Ridker; C H Hennekens; J P Miletich
Journal:  Circulation       Date:  1999-03-02       Impact factor: 29.690

3.  Extensive thrombus formation in the right ventricle due to a rare combination of arrhythmogenic right ventricular cardiomyopathy and heterozygous prothrombin gene mutation G20210 A.

Authors:  C H Attenhofer Jost; T Bombeli; C Schrimpf; E Oechslin; W Kiowski; R Jenni
Journal:  Cardiology       Date:  2000       Impact factor: 1.869

Review 4.  Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.

Authors:  Wai Khoon Ho; Graeme J Hankey; Daniel J Quinlan; John W Eikelboom
Journal:  Arch Intern Med       Date:  2006-04-10

5.  Familial thrombophilia and the prothrombin 20210A mutation: association with increased thrombin generation and unusual thrombosis.

Authors:  J W Eikelboom; L Ivey; J Ivey; R I Baker
Journal:  Blood Coagul Fibrinolysis       Date:  1999-01       Impact factor: 1.276

6.  Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years.

Authors:  Wolfgang Lalouschek; Martin Schillinger; Kety Hsieh; Georg Endler; Susanne Tentschert; Wilfried Lang; Suzanne Cheng; Christine Mannhalter
Journal:  Stroke       Date:  2005-06-09       Impact factor: 7.914

Review 7.  Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies.

Authors:  Robert J Kim; Richard C Becker
Journal:  Am Heart J       Date:  2003-12       Impact factor: 4.749

8.  Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model.

Authors:  R Vink; R A Kraaijenhagen; M Levi; H R Büller
Journal:  J Thromb Haemost       Date:  2003-12       Impact factor: 5.824

9.  Left ventricular thrombus in the absence of detectable heart disease.

Authors:  S A Vaganos; K R Fox; J G Kitchen
Journal:  Chest       Date:  1989-08       Impact factor: 9.410

10.  Left ventricular thrombus sans overt cardiac pathology.

Authors:  Om P Yadava; Sumit Yadav; Saurabh Juneja; Vijay K Chopra; Rajeev Passey; Rajen Ghadiok
Journal:  Ann Thorac Surg       Date:  2003-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.